H.C. Wainwright keeps USD 3.00 target for OPKO Health stock

Published on 10/20/2026 at 18:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Q2 revenue reached USD 163.60 million, up 4.30 percent year over year. OPKO Health stock costs EUR 1.51 on October 20, 2026 at 6:39 p.m. CEST.

Analyst target and quarterly results

H.C. Wainwright reiterated a Buy rating and a USD 3.00 target on October 16, 2026.
Second-quarter 2026 revenue reached USD 163.60 million, up 4.30 percent year over year.
OPKO Health stock costs EUR 1.51 at Lang & Schwarz on October 20, 2026 at 6:39 p.m. CEST.

OPK, US68375N1037, Illustration mit AI erstellt.

H.C. Wainwright reiterated a Buy rating and a USD 3.00 price target for OPKO Health on October 16, 2026, according to Investing.com. At Lang & Schwarz, OPKO Health was trading at EUR 1.51 on October 20, 2026 at 6:39 p.m. CEST.

Quarterly figures improved

OPKO reported total revenue of USD 163.60 million for the second quarter of 2026, an increase of 4.30 percent from the same period a year earlier. The figure exceeded H.C. Wainwright's USD 130.00 million forecast, while the company posted an adjusted loss of USD 0.01 per share against a consensus loss of USD 0.08, Investing.com reported on October 16, 2026.

Pharmaceuticals revenue increased to USD 42.90 million in the second quarter of 2026, up 5.40 percent year over year. Rayaldee revenue rose to USD 8.10 million from USD 7.20 million in the second quarter of 2025, according to the same report.

Nasdaq price and valuation

OPK was last at USD 1.70 on the Nasdaq on October 20, 2026 at 12:46 p.m. ET. The quote was USD 0.09 above the prior session's USD 1.61, equal to a 5.59 percent increase on the Nasdaq. OPKO Health's market capitalization was USD 1.3 billion on October 20, 2026.

The stock's 52-week range was USD 0.98 to USD 1.77 as of October 16, 2026. The negative trailing P/E of 17.77 reflects reported losses rather than a positive earnings multiple. OPKO Health combines diagnostics and pharmaceuticals, with BioReference Laboratories serving as its clinical laboratory business.

Company calendar and investor view

OPKO Health's investor-relations page identifies the second quarter of 2026 as its latest financial-results period and lists the October 15, 2026 announcement concerning Labcorp's agreement to acquire selected BioReference Health assets. The page also lists OPKO's participation in the Wells Fargo Healthcare Conference on September 8, 2026, OPKO Health states.

Price perspective

The analyst target remains materially above both the Nasdaq quote and the euro quotation, while the second-quarter figures provide a measurable operating comparison. The market capitalization and negative P/E show that the valuation still depends heavily on future earnings improvement.

At Lang & Schwarz, OPKO Health was trading at EUR 1.51 on October 20, 2026 at 6:39 p.m. CEST. On Nasdaq, OPK was last at USD 1.70 on October 20, 2026 at 12:46 p.m. ET. The further course of trading is shown by the continuously updated real-time quote of OPKO Health stock.